Menu
With Q4 earnings season upon us, better-than-expected gains from companies based partly or mostly on lower oil prices may be just the salve the market needs to regain some traction. More
Ebola stocks have doled out some big gains to savvy traders this year, but investors looking for Roche (RHHBY) to do the same may want to rethink their expectations. More
Gilead's breakthrough Hepatitis C drug, Sovaldi®, will drive revenue and profits for the rest of 2014 and into 2015. More
Roche stock may not be an NYSE or NASDAQ-listed equity, but when you look at the details, RHHBY is plenty investment-worthy. More
Healthcare concerns in the U.S. are being addressed by companies in the industry. These 3 issues can lead investors to stock opportunities More
British drug maker AstraZeneca says the U.S. Department of Justice is investigating a clinical trial of its Brilinta heart drug. More
A big week for earnings and dividend increases includes these 8 stocks in our portfolio. More
